Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$97.74 -1.0%	$88.49	$73.04 ▼ $121.90	$6.31B	0.83	780,742 shs	621,844 shs
FPRX Five Prime Therapeutics	$38.00	$37.94	$2.61 ▼ $38.90	$1.77B	4.4	1.98 million shs	N/A
MDGL Madrigal Pharmaceuticals	$294.64 -1.6%	$322.18	$200.63 ▼ $377.46	$6.54B	-0.91	386,062 shs	305,937 shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$17.18 +0.8%	$17.11	$13.61 ▼ $30.36	$5.80B	N/A	27,361 shs	13,101 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	-1.23%	-6.59%	+19.12%	-6.90%	-10.15%
FPRX Five Prime Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MDGL Madrigal Pharmaceuticals	-1.65%	-6.61%	-6.15%	-11.45%	+41.63%
TLX Telix Pharmaceuticals Limited American Depositary Shares	+0.46%	-8.13%	+7.98%	-4.82%	+1,717,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	2.5616 of 5 stars	4.4	1.0	0.0	0.0	2.9	0.8	0.6
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	4.6092 of 5 stars	4.5	0.0	0.0	4.6	3.4	4.2	0.6
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.83	Moderate Buy	$126.56	29.49% Upside
FPRX Five Prime Therapeutics	0.00	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	2.90	Moderate Buy	$416.33	41.30% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	28.06% Upside

Current Analyst Ratings Breakdown

Latest FPRX, MDGL, BPMC, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	BPMC Blueprint Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$135.00 ➝ $135.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00
5/2/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$394.00 ➝ $420.00
5/1/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$128.00
4/28/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$133.00 ➝ $130.00
4/24/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$443.00 ➝ $443.00
4/16/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$128.00 ➝ $128.00
4/8/2025	BPMC Blueprint Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$133.00 ➝ $133.00
3/20/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$120.00 ➝ $100.00
3/18/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	11.23	N/A	N/A	$4.67 per share	20.93
FPRX Five Prime Therapeutics	$14.87M	119.01	N/A	N/A	$4.13 per share	9.20
MDGL Madrigal Pharmaceuticals	$317.38M	20.61	N/A	N/A	$20.53 per share	14.35
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.41	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	150.37	N/A	-13.19%	-77.49%	-20.84%	N/A
FPRX Five Prime Therapeutics	-$137.20M	-$3.92	N/A	N/A	N/A	-554.71%	-75.84%	-49.08%	N/A
MDGL Madrigal Pharmaceuticals	-$373.63M	-$18.05	N/A	N/A	N/A	N/A	-71.78%	-53.25%	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	35.79	N/A	N/A	N/A	N/A	N/A

Latest FPRX, MDGL, BPMC, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million
2/26/2025	Q4 2024	MDGL Madrigal Pharmaceuticals	-$4.32	-$2.71	+$1.61	-$2.71	$97.81 million	$103.32 million
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
FPRX Five Prime Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
FPRX Five Prime Therapeutics	N/A	5.35	5.35
MDGL Madrigal Pharmaceuticals	0.15	5.98	5.93
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
FPRX Five Prime Therapeutics	67.28%
MDGL Madrigal Pharmaceuticals	98.50%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
FPRX Five Prime Therapeutics	6.40%
MDGL Madrigal Pharmaceuticals	22.80%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
FPRX Five Prime Therapeutics	87	46.57 million	N/A	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	16.84 million	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	337.88 million	N/A	N/A

FPRX, MDGL, BPMC, and TLX Headlines

Recent News About These Companies

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7 at 4:13 PM | globenewswire.com

Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX

May 7 at 7:30 AM | accessnewswire.com

ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

May 6, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 5, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Still a Buy?

May 5, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Time to Buy?

May 4, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)

May 2, 2025 | accessnewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (TLX)

May 1, 2025 | nasdaq.com

TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation

May 1, 2025 | accessnewswire.com

What is William Blair's Estimate for TLX FY2026 Earnings?

May 1, 2025 | marketbeat.com

William Blair Issues Pessimistic Forecast for TLX Earnings

May 1, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - What's Next?

April 30, 2025 | marketbeat.com

TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited

April 30, 2025 | accessnewswire.com

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

April 28, 2025 | globenewswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud

April 28, 2025 | accessnewswire.com

Telix shares crash 8% on US FDA blow

April 27, 2025 | msn.com

Telix Pharmaceuticals Ltd. ADR

April 23, 2025 | wsj.com

Telix Reports US$186M Q1 Revenue, Up 62% YOY

April 22, 2025 | globenewswire.com

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

April 15, 2025 | globenewswire.com

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

April 14, 2025 | zacks.com

Telix Shares May Gain on the Distribution Deal With Cardinal Health

April 9, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FPRX, MDGL, BPMC, and TLX Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$97.74 -1.02 (-1.03%)

As of 05/9/2025 03:52 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$294.64 -4.93 (-1.65%)

As of 05/9/2025 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$17.18 +0.13 (+0.76%)

As of 05/9/2025 03:59 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time